XGEVA (Denosumab) for Lung Cancer: Survival Benefit Suggested by Retrospective Subset Analysis of Key Trial Article Late last year, I reviewed the approval of the agent XGEVA (denosumab) for patients with skeletal metastases from solid tumors after a randomized phase III trial demonstrated a significant reduction in the rate of development of skeletal-related events compared with the pre-existing standard of Zometa (zoledronic acid) for bone metastases. Read more about XGEVA (Denosumab) for Lung Cancer: Survival Benefit Suggested by Retrospective Subset Analysis of Key Trial11 comments